Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 25, 2011

FDA Approves Graceway's Once-Daily Genital Warts Cream

  • FDA has cleared Graceway® Pharmaceuticals’ once-daily Zyclara® 3.75% Cream (imiquimod) for the topical treatment of external genital and perianal warts in patients aged 12 years and over. Approval was based on data from two Phase III placebo-controlled studies that showed that on an intent-to-treat basis, 28.3% of patients using imiquimod achieved complete clearance of all warts, compared with 9.4% of patients using a placebo cream.

    Efficacy was greater in females than males for all primary and secondary efficacy measures, the firm notes. 37% of all females using imiquimod cream achieved complete wart clearance, compared with 19% of males. The overall recurrence rate among all imiquimod cohort subjects who achieved complete clearance was 15% within 12 weeks

    “Many of the currently approved topical treatments for genital warts are not ideal due to lengthy and confusing dosing regimens,” comments Jefferson J. Gregory, chairman and CEO at Graceway. “Our vision for Zyclara Cream is to improve patient experience by offering a more intuitive dosing regimen (once daily treatment for up to eight weeks) with the goal of improving patient compliance.”



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »